Delving into Acromegaly

Störmann, Sylvère; Schilbach, Katharina

doi:10.3390/jcm12041654

Cited by 4 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…size of the body, joint pain, visual problems, hypertension, diabetes mellitus, heart failure, and respiratory failure are in most cases the presenting clinical conditions. 1,2,3 The majority of these are common conditions in medical practice and thus, there are chances that the underlying growth hormone excess might escape consideration. 9,10 This article presents the clinical details of four acromegaly patients, not presenting to an endocrinologist but to the internal medicine department with apparently 'common' medical issues.…”

Section: Case Series Original Article Original Article Original Artic...mentioning

confidence: 99%

See 1 more Smart Citation

Recognizing the Diverse Clinical Presentations of Acromegaly: Insight from a Case Series

Salam MU,

Jabeen R,

Ahmad MM

et al. 2024

JSWMC

View full text Add to dashboard Cite

Purpose: Acromegaly is an endocrine disease due to growth hormone excess with slowly developing manifestations and diverse clinical presentations. There are chances that patients may present with common clinical problems and the underlying endocrine condition is overlooked and diagnosis is delayed. This case series will discuss the presentation, clinical features and investigations of four acromegaly cases to increase the clinical skills of physicians so that an early diagnosis is made and treatment is initiated early. Methods: This is an observational study, where a series of four acromegaly cases, who presented to medicine inpatients or outpatients of Sylhet Women’s Medical College, Bangladesh. They were analyzed through detailed clinical features and, investigation findings. MRI brain was used as the main tool for diagnosis. Serum levels of growth hormone, IGF-1, TSH, ACTH, and prolactin were assessed in all. Other anterior pituitary hormone assays were selectively done. Ocular examinations were performed on all patients. Conclusion: Though a case series has lower value as medical evidence than systematic reviews and randomized clinical trials, it can help in generating future protocols of studies. This series emphasizes that a keen clinical eye of the physician can help in early diagnosis of acromegaly and thus an early MRI of brain based on clinical suspicion can ensure early treatment and prevent cardiovascular complications.

show abstract

Section: Case Series Original Article Original Article Original Artic...mentioning

confidence: 99%

“…Its annual prevalence is 50-80 per 100,000 population across the globe 1 and, it has a diverse clinical presentation that might involve, almost all systems of the body. However, the facial and acral features are striking and a careful look often illuminates a diagnosis.…”

Section: Introductionmentioning

confidence: 99%

Recognizing the Diverse Clinical Presentations of Acromegaly: Insight from a Case Series

Salam MU,

Jabeen R,

Ahmad MM

et al. 2024

JSWMC

View full text Add to dashboard Cite

show abstract

“…Lactotroph Pharmacologic (DA) [11] TSS [12][13] RT [14] Somatotroph TSS [15] Pharmacologic [16] RT [14] Corticotroph TSS [17] Pharmacologic (adrenal enzyme inhibitors, adrenolytic agents, or glucocorticoid-receptor antagonists) [19] RT [14] Bilateral total adrenalectomy (may be preferred by the patient) * [20] RT (for children under age 18 years) * [18] Thyrotroph TSS Pharmacologic (somatostatin analogues) [22] RT [23] Pharmacologic before surgery to restore euthyroidism (somatostatin analogues) * [21] Gonadotroph TSS [24] RT [25] -Non-functioning TSS [24] RT [25] -…”

Section: Adenoma Type First Line [Ref] Second Line [Ref] Third Line [...mentioning

confidence: 99%

Metabolic Syndrome Components in Patients with Pituitary Adenoma

Gonzalez-Almazan,

Cortes-Contreras,

Flores-Rabasa

et al. 2023

Horm Metab Res

View full text Add to dashboard Cite

Pituitary adenomas are benign tumors of the anterior portion of the pituitary gland (adenohypophysis), representing the 25% of all the tumor alterations. Pituitary adenomas are classified by the type of hormone secreted, cellularity, size, and structural alterations by the hormonal segregation. The diagnosis consists on the histopathological identification of cell types and the image-guided by magnetic resonance or tomography; the treatment can be both pharmacological and surgical. Metabolic Syndrome is the set of clinical conditions that increase the risk of cardiovascular diseases with an estimated prevalence of 25% worldwide. The alterations of metabolic syndrome are obesity, hypertension, dyslipidemia, insulin resistance, and diabetes mellitus type II. Pituitary adenomas and metabolic syndrome have an important relationship, hormone-secreting by pituitary adenomas affects a myriad of signaling pathways, which allows a favorable environment for the appearance of the metabolic syndrome. Moreover, patients with pituitary adenomas are shown to have an improvement in metabolic parameters after the medical/surgical treatment. The objective of this review is to explore the possible mechanisms through which PAs contributes to MetSx.

show abstract

“…Acromegaly is a rare endocrine disorder typically caused by a pituitary tumour and characterized by excessive secretion of growth hormone (GH) and insulin-like growth factor 1 (IGF1), its target hormone. 1 , 2 In a recent review and meta-analysis, the pooled prevalence of acromegaly was estimated at around 59 cases per million people worldwide, with an incidence of 3.8 per million person-years and considerable regional variability. 3 However, estimates on prevalence and incidence may greatly vary according to regional differences, with prevalence estimates ranging from 28 to 137 cases per million population and incidence ranging from 2 to 12 cases per million person-years.…”

Section: Introductionmentioning

confidence: 99%

Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences

Chiloiro,

Appetecchia,

Bianchi

et al. 2024

DIC

View full text Add to dashboard Cite

Pasireotide-LAR is recommended as a second-line treatment for patients with acromegaly. Although the effects of pasireotide-LAR have been well characterized in clinical studies, real-practice evidence is scant, especially in the long term and within the individualization of therapy in patients with comorbidities. To provide additional insight on the individualized approach to acromegaly management, six clinical cases of complex acromegaly treated with pasireotide-LAR for more than 5 years were reported. Pasireotide-LAR allowed the normalization of insulin-like growth factor 1 (IGF1) values in all patients and reduced tumour residue volume where present. A good safety profile and long-term tolerability were also reported.

show abstract

Delving into Acromegaly

Abstract: Acromegaly is a rare and disabling disease with some distinct and striking clinical features that have fascinated (and frightened) laypeople and medical experts alike throughout history [...]

Cited by 4 publications

References 24 publications

Recognizing the Diverse Clinical Presentations of Acromegaly: Insight from a Case Series

Recognizing the Diverse Clinical Presentations of Acromegaly: Insight from a Case Series

Metabolic Syndrome Components in Patients with Pituitary Adenoma

Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences

Contact Info

Product

Resources

About